Browse News

Found 5,174 articles

• Heidelberg Pharma Reports Outcome Of Annual General Meeting

  5/21/2019

  Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities during the Annual General Meeting.

• Bulletin From The Annual General Meeting in Oncopeptides Ab (publ)

  5/21/2019

  Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed.

• PatientPoint Content Earns Top Honors from Hermes Creative Awards

  5/21/2019

  The Hermes Creative Awards, one of the world's largest competitions honoring the messengers and creators of traditional and emerging media, has awarded best-in-industry content from PatientPoint® with 12 Platinum and Gold awards for outstanding creative

• Oncopeptides AB: INTERIM REPORT Q1 2019

  5/21/2019

  The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.

• Oncopeptides to Apply for Accelerated Approval in the US

  5/20/2019

  Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.

• Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer

  5/20/2019

  Merck announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy.

• Oncopeptides to Apply for Accelerated Approval in the US - May 20, 2019

  5/20/2019

  Oncopeptides AB announced that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.

• Krispy Krunchy® Joins The Leukemia & Lymphoma Society's Man & Woman of the Year in the Fight to Cure Blood Cancers

  5/17/2019

  Krispy Krunchy Chicken® just announced a collaboration with The Leukemia & Lymphoma Society's Man & Woman of the Year campaign to help drive forward LLS's goal of creating a world without blood cancers.

• Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses

  5/16/2019

  Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam.

• Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019

  5/16/2019

  New data on Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases

• bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress

  5/16/2019

  Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT

• Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting

  5/16/2019

  Flatiron Health announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago.

• Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

  5/16/2019

  Sutro Biopharma, Inc. announced that the company will present at the upcoming European Hematology Association Congress being held June 13-16, 2019, in Amsterdam.

• Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting

  5/16/2019

  Actinium Pharmaceuticals, Inc. announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago.

• Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

  5/16/2019

  New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months

• Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

  5/16/2019

  Oncopeptides AB announced that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association meeting.

• Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

  5/16/2019

  Oncopeptides AB announced that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma have been selected for poster presentation at the 2019 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4 in Chicago.

• Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics

  5/15/2019

  Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher

• AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

  5/15/2019

  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

• Krispy Krunchy® Announces Groundbreaking Partnership with The Leukemia & Lymphoma Society

  5/15/2019

  Krispy Krunchy Foods, LLC, will be donating 100% of their corporate profits from the sale of the Krispy Krunchy Chicken® Sandwich to The Leukemia & Lymphoma Society (LLS) where the money will go directly to fund research, help families, and save lives